What We’ve Learned About GLP-1 Agonists to Date

Some of these drugs reduce the risk of heart attack and stroke in people with diabetes and in obese individuals without diabetes.


Glucagon-like peptide-1 (GLP‑1) receptor agonists are a class of medication used to lower blood glucose (sugar) levels in individuals with type 2 diabetes. The first GLP-1, exenatide (Byetta), was approved in 2005. Multiple GLP-1 products and formulations are now available.

To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access